Point72 Asia (Singapore) Pte. Ltd. Savara Inc Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $381 Billion
- Q1 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Savara Inc stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 12,116 shares of SVRA stock, worth $37,559. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,116Holding current value
$37,559% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding SVRA
# of Institutions
143Shares Held
162MCall Options Held
54.8KPut Options Held
4.1K-
Nea Management Company, LLC Timonium, MD24.5MShares$75.9 Million6.43% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$54.6 Million16.36% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$38.3 Million8.25% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA11.5MShares$35.5 Million2.0% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$34.1 Million2.18% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $354M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.